febit Joins the READNA Consortium with its Sequence Capture Technology
News Mar 04, 2009
febit announces that the company will further advance its HybSelect technology for use in READNA projects. HybSelect enables automated capture of specific DNA regions for high-throughput sequencing and will soon be launched in several markets.
Joining a group of 16 European partners from industry and academics, febit will support the READNA consortium (REvolutionary Approaches and Devices for Nucleic Acid analysis).
In projects supported by the EU with 12 million Euros of funding, the consortium pursues the development and evaluation of trail-blazing new technologies for DNA sequencing.
febit CSO Peer Stahler is convinced that HybSelect will make an important contribution to these efforts: “Using our novel technology, we can quasi-automatically capture specific genes from samples, thus enabling highly efficient operation of next-generation sequencers by directing the sequencing process to the regions of interest to the researcher. Multiple samples may be sequenced in parallel for immediate analysis – saving time, cost and a great deal of effort in data analysis.“
For the research group of Dr. Ivo Gut, project coordinator and Associate Director of the Centre National de Genotypage (CNG) in Paris (France), febit will adapt its HybSelect technology for selected applications in next generation sequencing.
“We are very happy that we managed to get Europe’s most innovative researchers on board of the READNA project,“ Dr. Gut explains. “The project will help to advance biomedical science and open up new pathways in health care. The extraordinary quality of research in this consortium illustrates the importance and caliber of life sciences in Europe.“
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE